M Bio Technology Inc.

Novel diagnoses, prevention and therapeutics technologies for mycoplasma infectious diseases (MID)

Business information

Company name

M Bio Technology Inc.

Established

2005

Location

Tokyo, JP

Spinout from

Other location(s)

Chiba, JP

Technology validation

TRL

5

Value of patent(s)

Over $3m

Business stage

Series B stage / global alliance

Target exit

Licensing out

Next investment requirement

$10-20m

Message to the business partners

M Biotech has key patents for the structure of glycolipid on mycoplasma membrane surfaces as well as its synthesis methodology. These technologies could be applied both for high sensitive diagnoses and vaccine development with applying the glycolipid-antigen to produce its antibody. M Biotech encourages global business expansion with identifying the business and technical partners.

Company URL

Key literatures

Synthesis and absolute structures of Mycoplasma pneumoniae β-glyceroglycolipid antigens

Chemosynthetic homologues of Mycoplasma pneumoniae β-glycolipid antigens for the diagnosis of mycoplasma infectious diseases

Detection of serum antibodies against phosphocholine-containing aminoglycoglycerolipid specific to Mycoplasma fermentans in HIV-1 infected individuals